Abbott India Ltd (ABBOTINDIA) — shareholding pattern, promoter holding, financials and share price

About Abbott India Ltd (ABBOTINDIA)

Abbott India Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as ABBOTINDIA and on the BSE under scrip code 500488. Its ISIN is INE358A01014.

Abbott India Ltd is one of the leading multinational pharmaceutical companies in India and sells its products through independent distributors primarily within India. [1] It was established in 1944. [2]

Abbott India Ltd is a leading multinational pharmaceutical company with a manufacturing facility in Goa and various third-party manufacturers across India.

It operates in therapeutic areas such as Women's Health, Gastroenterology, Central Nervous System, Metabolics, Multi-Specialty, Vaccines, and Consumer Health, offering a diverse product portfolio.

Listed peers in Pharmaceuticals: Biocon Ltd, Alkem Laboratories Ltd, Glenmark Pharmaceuticals Ltd, Ipca Laboratories Ltd, Ajanta Pharma Ltd, Glaxosmithkline Pharmaceuticals Ltd.

Valuation & Returns

10 Jul 2026

At ₹27,124.95 a share on 10 Jul 2026, Abbott India Ltd (ABBOTINDIA) was valued at a price-to-earnings ratio of 37.14x against an industry P/E of 36.41x and a price-to-book of 13.62x on a book value of ₹1,992.14 per share as of Mar 2025. Solomo computes return on equity of 36.66% and return on capital employed of 47.5% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.

P/E
37.14x
Industry P/E
36.41x
P/B
13.62x
EPS (TTM)
₹730.39
Book value / share
₹1,992.14
ROE
36.66%
ROCE
47.5%
ROA
26.23%
Debt / equity
0.05x
Dividend yield
1.75%
EBITDA margin
31.46%
52-week range
₹25,164 – ₹35,280

Ratios are computed from filed results and the last recorded price. Not investment advice.

Financial Performance

Mar 2026

In the year ended Mar 2026, Abbott India Ltd (ABBOTINDIA) reported revenue of ₹6,929 crore, net profit of ₹1,552 crore and earnings per share of ₹730.39. That compares with revenue of ₹6,409 crore and net profit of ₹1,414 crore in Mar 2025. Figures are standalone, as filed with the exchanges.

In the quarter ended Mar 2026, revenue was ₹1,710 crore and net profit ₹395 crore (standalone).

Standalone annual results for Abbott India Ltd (ABBOTINDIA), Mar 2022 to Mar 2026. Revenue and net profit in ₹ crore; EPS in ₹ per share.
MetricMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue (₹ cr)4,9195,3495,8496,4096,929
Net profit (₹ cr)7999491,2011,4141,552
EPS (₹)375.87446.8565.3665.64730.39
Compound annual growth for Abbott India Ltd (ABBOTINDIA). Stock price CAGR is price return and excludes dividends.
Measure10Y5Y3Y1Y
Sales growth10.33%9.38%9.26%14.52%
Profit growth20.96%18.99%20.99%16.35%

Ownership Summary

Jun 2026

As of Jun 2026, promoters hold 74.99% of Abbott India Ltd (ABBOTINDIA) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0.38% and domestic institutional investors (DII) hold 8.78%. Market capitalisation was ₹57,639 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.

Largest disclosed public shareholders in Jun 2026: SBI NIFTY MIDCAP 150 MOMENTUM 50 ETF 1.92%, NIPPON LIFE INDIA TRUSTEE LTD 1.07%, CANARA ROBECO MUTUAL FUND 1.07%. Only stakes above the 1% disclosure threshold are named in filings.

QuarterPromoterPledgedFIIDIIPublic
Jun 202674.99%-0.38%8.78%25.01%
Mar 202674.99%-0.26%8.93%25.01%
Dec 202574.99%-0.18%9%25.01%
Sep 202574.99%-0.16%9.11%25.01%
Jun 202574.99%-0.16%9.19%25.01%
Mar 202574.99%-0.16%8.92%25.01%
Dec 202474.99%-0.16%9.01%25.01%
Sep 202474.99%-0.16%8.99%25.01%
Every quarter since Mar 2001 Filing data, not investment advice.